Latest Breaking News On - Investigational new drug - Page 5 : comparemela.com

Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study

Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.

United statesEduard gasalJulia wilsonMerck sharp dohmeMerck co incJw communicationsInvestigational new drugChief medical officerMerck sharp

Syncona : Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study

Syncona : Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesJulia wilsonEduard gasalMerck sharp dohmeMerck co incJw communicationsInvestigational new drugChief medical officerMerck sharp

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.

United statesSulfated proteoglycansCommittee for medicinal products humanEuropean medicines agencyDrug administrationVirus killing technology platformSecurities exchangeExchange commissionNanoviricides incTheracour pharma incNovel host mimeticVirus killing technologyMimetic technology to solveGreatest painAntiviral medicinesBroad antiviral spectrum

CDR-Life Inc : CDR-Life Announces Initiation of CDR404 Phase 1 Trial for Treatment of Solid Tumors at ASCO

CDR-Life Inc. today announced the initiation of enrollment for the Phase 1 trial of CDR404, its lead program in development as a precision immunotherapy for solid tumors. CDR404 will be the focus of

United statesLauren arnoldChristian leisnerAmerican society of clinical oncologyClinical oncologyAnnual meetingInvestigational new drugClinical trial applicationChief executive officerDougall advisorsIhr portfolio

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel

BOSTON, May 29, 2024 (GLOBE NEWSWIRE) TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced new preliminary data

United statesTania montgomery hammonDaniel vlockZdravka medarovaExchange commissionTranscode therapeutics incBusiness developmentCode therapeuticsChief scientific officerChief medicalPrivate securities litigation reform actInvestigational new drugAnnual report